肌层浸润性膀胱癌-话题@MedSci

#肌层浸润性膀胱癌#

36篇内容 | 2184人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2219558, encodeId=228a221955886, content=<a href='/topic/show?id=d29c15166f9' target=_blank style='color:#2F92EE;'>#RB1#</a> <a href='/topic/show?id=222f2951f5' target=_blank style='color:#2F92EE;'>#ATM#</a> <a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a> <a href='/topic/show?id=322811e75386' target=_blank style='color:#2F92EE;'>#ERCC2#</a> <a href='/topic/show?id=f1c911e754de' target=_blank style='color:#2F92EE;'>#FANCC#</a>, objectTitle=Eur. Urol | ATM、RB1、ERCC2 和 FANCC 基因突变：预测肌层浸润性膀胱癌治疗反应的潜在生物标志物, objectType=article, longId=838529, objectId=8bf483852982, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231103/1698995635796_8096338.jpg, objectUrl=/article/show_article.do?id=8bf483852982, replyNumber=0, likeNumber=49, createdTime=2024-08-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8bf483852982, moduleTitle=Eur. Urol | ATM、RB1、ERCC2 和 FANCC 基因突变：预测肌层浸润性膀胱癌治疗反应的潜在生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bf483852982)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209934, encodeId=929622099346c, content=<a href='/topic/show?id=d17466492d5' target=_blank style='color:#2F92EE;'>#溶瘤病毒#</a> <a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=“以毒攻毒”抗癌，近60%患者完全缓解！溶瘤病毒展现强大抗肿瘤活性, objectType=article, longId=830108, objectId=8d8783010852, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240614/1718359772095_5579292.jpg, objectUrl=/article/show_article.do?id=8d8783010852, replyNumber=0, likeNumber=61, createdTime=2024-06-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8d8783010852, moduleTitle=“以毒攻毒”抗癌，近60%患者完全缓解！溶瘤病毒展现强大抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d8783010852)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192786, encodeId=03ad2192e8682, content=<a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他滨#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=读书报告 | 吉西他滨联合顺铂和纳武利尤单抗作为肌层浸润性膀胱癌器官保留治疗的2期临床试验, objectType=article, longId=816649, objectId=71088166495e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668021554762_4754896.jpeg, objectUrl=/article/show_article.do?id=71088166495e, replyNumber=0, likeNumber=195, createdTime=2024-03-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=71088166495e, moduleTitle=读书报告 | 吉西他滨联合顺铂和纳武利尤单抗作为肌层浸润性膀胱癌器官保留治疗的2期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71088166495e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183117, encodeId=ee98218311eaf, content=<a href='/topic/show?id=1cf64063952' target=_blank style='color:#2F92EE;'>#围手术期#</a> <a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a> <a href='/topic/show?id=a7901103555e' target=_blank style='color:#2F92EE;'>#3期研究#</a>, objectTitle=Lancet Oncol：围手术期大剂量甲氨蝶呤、长春碱、阿霉素和顺铂治疗肌层浸润性膀胱癌（VESPER）：一项开放标签、随机、3期研究中5年的生存终点, objectType=article, longId=810429, objectId=cf69810429c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240121/1705849215237_6145188.png, objectUrl=/article/show_article.do?id=cf69810429c7, replyNumber=0, likeNumber=132, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cf69810429c7, moduleTitle=Lancet Oncol：围手术期大剂量甲氨蝶呤、长春碱、阿霉素和顺铂治疗肌层浸润性膀胱癌（VESPER）：一项开放标签、随机、3期研究中5年的生存终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf69810429c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177570, encodeId=d81521e7570b1, content=<a href='/topic/show?id=f0838291817' target=_blank style='color:#2F92EE;'>#肿瘤微环境#</a> <a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a> <a href='/topic/show?id=6b5710929680' target=_blank style='color:#2F92EE;'>#化学免疫疗法#</a>, objectTitle=Eur Urol：肿瘤微环境中的空间关系与肌层浸润性膀胱癌中新辅助化学免疫疗法的病理反应有关, objectType=article, longId=807058, objectId=808580e05874, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231227/1703647183637_1935437.jpg, objectUrl=/article/show_article.do?id=808580e05874, replyNumber=0, likeNumber=74, createdTime=2023-12-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=808580e05874, moduleTitle=Eur Urol：肿瘤微环境中的空间关系与肌层浸润性膀胱癌中新辅助化学免疫疗法的病理反应有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=808580e05874)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2165686, encodeId=f5eb216568630, content=<a href='/topic/show?id=75a16223199' target=_blank style='color:#2F92EE;'>#根治性膀胱切除术#</a>是<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>（MIBC）患者的标准治疗。然而，根治性膀胱切除术有重大<a href='/topic/show?id=1cf64063952' target=_blank style='color:#2F92EE;'>#围手术期#</a><a href='/topic/show?id=0e1a4903251' target=_blank style='color:#2F92EE;'>#并发症#</a>的风险，并可能损害患者的生活质量。为了解决这些问题，最近的指南推荐使用多模式治疗（MTT）的保膀胱策略，通常包括最大限度的<a href='/topic/show?id=142610e29177' target=_blank style='color:#2F92EE;'>#经尿道切除#</a>（TUR）和化学<a href='/topic/show?id=d2ba5e382ac' target=_blank style='color:#2F92EE;'>#放射治疗#</a>（CRT）作为MIBC患者的一个替代选择。, objectTitle=European Radiology:VI-RADS在肌层浸润性膀胱癌多模式治疗中的新用途, objectType=article, longId=798508, objectId=5691e9850871, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301029/1698587725251_1605392.png, objectUrl=/article/show_article.do?id=5691e9850871, replyNumber=0, likeNumber=129, createdTime=2023-10-30, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5691e9850871, moduleTitle=European Radiology:VI-RADS在肌层浸润性膀胱癌多模式治疗中的新用途, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5691e9850871)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=1662668, encodeId=46b9166266885, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估, objectType=article, longId=735447, objectId=b7ffe3544777, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7ffe3544777, replyNumber=0, likeNumber=109, createdTime=2023-01-08, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7ffe3544777, moduleTitle=Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7ffe3544777)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662667, encodeId=46f9166266ef5, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析, objectType=article, longId=732583, objectId=f259e3258327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f259e3258327, replyNumber=0, likeNumber=103, createdTime=2023-06-21, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f259e3258327, moduleTitle=Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f259e3258327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662665, encodeId=78e6166266527, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Eur Urol Oncol：膀胱内VPM1002BC治疗常规BCG治疗后的非肌层浸润性膀胱癌(NMIBC)复发, objectType=article, longId=294582, objectId=5111294582d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5111294582d5, replyNumber=0, likeNumber=124, createdTime=2022-09-01, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5111294582d5, moduleTitle=Eur Urol Oncol：膀胱内VPM1002BC治疗常规BCG治疗后的非肌层浸润性膀胱癌(NMIBC)复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5111294582d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662657, encodeId=06b7166265ea2, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Eur Urol Oncol：全基因组meta分析发现与非肌层浸润性膀胱癌复发和进展相关的新基因, objectType=article, longId=215676, objectId=b05a2156e625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b05a2156e625, replyNumber=0, likeNumber=92, createdTime=2022-01-12, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b05a2156e625, moduleTitle=Eur Urol Oncol：全基因组meta分析发现与非肌层浸润性膀胱癌复发和进展相关的新基因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b05a2156e625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662662, encodeId=dcf816626624d, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=J Urol：非肌层浸润性膀胱癌中，淋巴结切除术是否能够改善根治性膀胱切除术的治疗效果？, objectType=article, longId=220931, objectId=68b0220931cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68b0220931cf, replyNumber=0, likeNumber=79, createdTime=2022-10-21, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68b0220931cf, moduleTitle=J Urol：非肌层浸润性膀胱癌中，淋巴结切除术是否能够改善根治性膀胱切除术的治疗效果？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68b0220931cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662666, encodeId=e4ce1662666a2, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Int J Urol：非肌层浸润性膀胱癌患者的分层是否有助于确定根治性膀胱切除术的适用人群？, objectType=article, longId=301683, objectId=7879301683a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7879301683a0, replyNumber=0, likeNumber=134, createdTime=2022-11-14, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7879301683a0, moduleTitle=Int J Urol：非肌层浸润性膀胱癌患者的分层是否有助于确定根治性膀胱切除术的适用人群？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7879301683a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662659, encodeId=c7e01662659d4, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, objectType=article, longId=216311, objectId=0e3021631188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3021631188, replyNumber=0, likeNumber=110, createdTime=2022-07-22, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3021631188, moduleTitle=J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3021631188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662660, encodeId=2d7f1662660e0, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=J Urol：哪类肌层浸润性膀胱癌患者从铂基新辅助化疗中获益很大？, objectType=article, longId=219531, objectId=8aec2195316c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8aec2195316c, replyNumber=0, likeNumber=148, createdTime=2022-05-07, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8aec2195316c, moduleTitle=J Urol：哪类肌层浸润性膀胱癌患者从铂基新辅助化疗中获益很大？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8aec2195316c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662650, encodeId=b34a166265009, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=BJU Int：上尿路癌对非肌层浸润性膀胱癌患者卡介苗反应的影响, objectType=article, longId=207720, objectId=556720e720df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556720e720df, replyNumber=0, likeNumber=141, createdTime=2021-11-20, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556720e720df, moduleTitle=BJU Int：上尿路癌对非肌层浸润性膀胱癌患者卡介苗反应的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556720e720df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662664, encodeId=2e87166266487, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=BJU Int：非肌层浸润性膀胱癌患者在BCG期间是否应停用纤维蛋白凝块抑制剂？, objectType=article, longId=291860, objectId=69f029186024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69f029186024, replyNumber=0, likeNumber=84, createdTime=2022-08-16, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69f029186024, moduleTitle=BJU Int：非肌层浸润性膀胱癌患者在BCG期间是否应停用纤维蛋白凝块抑制剂？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69f029186024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662663, encodeId=b6cf16626631b, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药, objectType=article, longId=221841, objectId=a33c221841fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a33c221841fa, replyNumber=0, likeNumber=85, createdTime=2022-11-11, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a33c221841fa, moduleTitle=凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a33c221841fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662661, encodeId=1abd166266194, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Clinical Nutrition: 非肌层浸润性膀胱癌患者术前腹部脂肪分布和全身免疫炎症与膀胱内卡介苗免疫治疗反应相关, objectType=article, longId=220096, objectId=48bc22009603, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48bc22009603, replyNumber=0, likeNumber=131, createdTime=2022-08-11, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48bc22009603, moduleTitle=Clinical Nutrition: 非肌层浸润性膀胱癌患者术前腹部脂肪分布和全身免疫炎症与膀胱内卡介苗免疫治疗反应相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48bc22009603)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662655, encodeId=78171662655ce, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Eur Urol：抗生素治疗对接受新辅助Pembrolizumab治疗的肌层浸润性膀胱癌患者是否有不利影响？ , objectType=article, longId=213080, objectId=46dd21308067, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46dd21308067, replyNumber=0, likeNumber=82, createdTime=2022-04-23, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46dd21308067, moduleTitle=Eur Urol：抗生素治疗对接受新辅助Pembrolizumab治疗的肌层浸润性膀胱癌患者是否有不利影响？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46dd21308067)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662658, encodeId=9629166265815, content=<a href='/topic/show?id=41218091691' target=_blank style='color:#2F92EE;'>#肌层浸润性膀胱癌#</a>, objectTitle=Cancers (Basel)：CNGB1作为肌层浸润性膀胱癌新辅助化疗反应的预测因素研究 , objectType=article, longId=215790, objectId=d45f215e9030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d45f215e9030, replyNumber=0, likeNumber=0, createdTime=2021-10-07, rootId=0, userName=12498768m21(暂无昵称), userId=3dd925444855, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d45f215e9030, moduleTitle=Cancers (Basel)：CNGB1作为肌层浸润性膀胱癌新辅助化疗反应的预测因素研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d45f215e9030)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肌层浸润性膀胱癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#RB1# #ATM# #肌层浸润性膀胱癌# #ERCC2# #FANCC#

Eur. Urol | ATM、RB1、ERCC2 和 FANCC 基因突变：预测肌层浸润性膀胱癌治疗反应的潜在生物标志物

2024-08-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#溶瘤病毒# #肌层浸润性膀胱癌#

“以毒攻毒”抗癌，近60%患者完全缓解！溶瘤病毒展现强大抗肿瘤活性

2024-06-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#吉西他滨# #纳武利尤单抗# #肌层浸润性膀胱癌#

读书报告 | 吉西他滨联合顺铂和纳武利尤单抗作为肌层浸润性膀胱癌器官保留治疗的2期临床试验

2024-03-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#围手术期# #肌层浸润性膀胱癌# #3期研究#

Lancet Oncol：围手术期大剂量甲氨蝶呤、长春碱、阿霉素和顺铂治疗肌层浸润性膀胱癌（VESPER）：一项开放标签、随机、3期研究中5年的生存终点

2024-01-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肿瘤微环境# #肌层浸润性膀胱癌# #化学免疫疗法#

Eur Urol：肿瘤微环境中的空间关系与肌层浸润性膀胱癌中新辅助化学免疫疗法的病理反应有关

2023-12-27发表于上海

(审核中...)

前往app查看评论内容

全文收起 #根治性膀胱切除术#是#肌层浸润性膀胱癌#（MIBC）患者的标准治疗。然而，根治性膀胱切除术有重大#围手术期##并发症#的风险，并可能损害患者的生活质量。为了解决这些问题，最近的指南推荐使用多模式治疗（MTT）的保膀胱策略，通常包括最大限度的#经尿道切除#（TUR）和化学#放射治疗#（CRT）作为MIBC患者的一个替代选择。

European Radiology:VI-RADS在肌层浸润性膀胱癌多模式治疗中的新用途

2023-10-30发表于上海

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估

2023-01-08

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Eur Urol Oncol：甲氨蝶呤、长春碱、阿霉素和顺铂在肌层浸润性膀胱癌患者中的安全性和有效性分析

2023-06-21

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Eur Urol Oncol：膀胱内VPM1002BC治疗常规BCG治疗后的非肌层浸润性膀胱癌(NMIBC)复发

2022-09-01

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Eur Urol Oncol：全基因组meta分析发现与非肌层浸润性膀胱癌复发和进展相关的新基因

2022-01-12

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

J Urol：非肌层浸润性膀胱癌中，淋巴结切除术是否能够改善根治性膀胱切除术的治疗效果？

2022-10-21

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Int J Urol：非肌层浸润性膀胱癌患者的分层是否有助于确定根治性膀胱切除术的适用人群？

2022-11-14

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

J Clin Oncol：肌层浸润性膀胱癌根治性切除术前予以吉西他滨+顺铂+派姆单抗新辅助疗法的效果

2022-07-22

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

J Urol：哪类肌层浸润性膀胱癌患者从铂基新辅助化疗中获益很大？

2022-05-07

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

BJU Int：上尿路癌对非肌层浸润性膀胱癌患者卡介苗反应的影响

2021-11-20

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

BJU Int：非肌层浸润性膀胱癌患者在BCG期间是否应停用纤维蛋白凝块抑制剂？

2022-08-16

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

凌腾医药宣布，卡妥索双抗用于介苗治疗失败的非肌层浸润性膀胱癌的1期临床试验已完成首例患者给药

2022-11-11

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Clinical Nutrition: 非肌层浸润性膀胱癌患者术前腹部脂肪分布和全身免疫炎症与膀胱内卡介苗免疫治疗反应相关

2022-08-11

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Eur Urol：抗生素治疗对接受新辅助Pembrolizumab治疗的肌层浸润性膀胱癌患者是否有不利影响？

2022-04-23

12498768m21(暂无昵称) (审核中...)

前往app查看评论内容

#肌层浸润性膀胱癌#

Cancers (Basel)：CNGB1作为肌层浸润性膀胱癌新辅助化疗反应的预测因素研究

2021-10-07

科室
- - 订阅+
  - 更多科室
工具
服务